U.S. Markets close in 5 hrs 17 mins
  • S&P 500

    3,831.96
    +10.41 (+0.27%)
     
  • Dow 30

    31,109.88
    +162.89 (+0.53%)
     
  • Nasdaq

    11,205.80
    +24.26 (+0.22%)
     
  • Russell 2000

    1,715.81
    -23.03 (-1.32%)
     
  • Crude Oil

    113.83
    +2.07 (+1.85%)
     
  • Gold

    1,817.40
    -3.80 (-0.21%)
     
  • Silver

    20.69
    -0.18 (-0.85%)
     
  • EUR/USD

    1.0483
    -0.0042 (-0.3984%)
     
  • 10-Yr Bond

    3.1280
    -0.0780 (-2.43%)
     
  • Vix

    28.39
    +0.03 (+0.11%)
     
  • GBP/USD

    1.2130
    -0.0054 (-0.4440%)
     
  • USD/JPY

    136.7950
    +0.6670 (+0.4900%)
     
  • BTC-USD

    20,088.48
    -709.41 (-3.41%)
     
  • CMC Crypto 200

    433.56
    -6.10 (-1.39%)
     
  • FTSE 100

    7,324.84
    +1.43 (+0.02%)
     
  • Nikkei 225

    26,804.60
    -244.87 (-0.91%)
     

Biofrontera Inc. to Report First Quarter Financial Results on May 13, 2022

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Biofrontera Inc.
Biofrontera Inc.

WOBURN, Mass., May 06, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, will report financial results for the three months ended March 31, 2022 before the opening of the U.S. financial markets on Friday, May 13, 2022 and will hold a conference call that same day beginning at 11:00 a.m. Eastern time to discuss those results, provide a business update and answer questions.

Conference Call and Webcast Information

Event:

Biofrontera Inc. First Quarter 2022 Financial Results and Business Update Conference Call

Date:

Friday, May 13, 2022

Time:

11:00 a.m. Eastern time

Conference call:

1-877-877-1275 (U.S.)
1-412-858-5202 (international)

Webcast:

Live and 90-day replay webcast are available here and at www.investors.biofrontera-us.com.

About Biofrontera Inc.

Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company’s licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. For more information, visit www.biofrontera-us.com.

Contacts

Biofrontera Inc.
Anke zur Mühlen
+1 781 486 1539
us-ir@biofrontera.com

LHA Investor Relations
Tirth T. Patel
+1 212 201 6614
tpatel@lhai.com

# # #